Up to now, two HDAC inhibitors, vorinostat (SAHA) and romidepsin (FK228), have been approved by FDA for the treatment of cutaneous T-cell lymphoma (CTCL) [21,22,23]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.